Research Grade Zeluvalimab (HS870276)

Datasheet Compartir producto Copiar información

Precio(USD): $

Especificación:

100ug
1mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet

Vista general

Número de catálogo

HS870276

Descripción

Zeluvalimab (HS870276) is a research-grade recombinant antibody targeting CD1. Produced in mammalian cells with native-like glycosylation.

Highlights

●Research Grade — For PK/PD studies, assay development, and ADA research.
●Native Glycosylation — Mammalian expression ensures native-like patterns.

Reactividad de especies

Human

Aplicaciones

ELISA, Bioactivity: FACS, Functional assay, Research in vivo, WB

Especie huésped

Humanized

Isotipo

IgG1-Kappa

Sistema de expresión

Mammalian Cells

Clonalidad

Monoclonal

Aplicaciones probadas

Objetivo

Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279

Nivel de endotoxinas

Please contact the lab for this information.

Pureza

>95% purity as determined by SDS-PAGE.

Purificación

Protein A/G purified from cell culture supernatant.

Número de acceso

Q15116

Forma

Liquid

Buffer de almacenamiento

0.01M PBS, pH 7.4.

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Información de uso del producto

Aplicación	Dilución
WB	1:500-1:2000

Estabilidad y almacenamiento

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

Nombres alternativos

AMG-404, AMG404, 2315361-37-4

Fondo

Programmed cell death protein 1 (CD279/PD-1) is a ~31 kDa protein. Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self. Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2. Following T-cell receptor (TCR) engagement, PDCD1 associates with TCR-CD3 in the immunological synapse and directly inhibits T-cell activation. Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta. CD279 is the therapeutic target of pembrolizumab (Keytruda) and nivolumab (Opdivo).

1. Fife, BT. et al. (2011) Annals of the New York Academy of Sciences 1217, 45-59. PMID: 21276005

2. Bardhan, K. et al. (2019) Scientific reports 9, 17252. PMID: 31754127

3. Patsoukis, N. et al. (2020) Communications biology 3, 128. PMID: 32184441

4. Xiao, X. et al. (2023) Nature communications 14, 2859. PMID: 37208329

5. Zak, KM. et al. (2015) Structure (London, England : 1993) 23, 2341-2348. PMID: 26602187

Nota

For research use only. Not suitable for clinical or therapeutic use.

Imágenes

SDS-PAGE

SDS-PAGE for Research Grade Zeluvalimab.
Bioactivity

Detects recombinant PD1 (Catalog No: HS870021) in indirect ELISA.
Western blot

Western blot analysis was performed using anti-PD1 monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human PD1 (Catalog No: HS870021)
Lane 2: Negative control